# US 2006/0052367 A1 · Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052367 A1
- Document ID: US20060052367A1
- Status: Published application
- Kind: A1
- Application number: 10/535,000
- Filed: 2003-11-17
- Published: 2006-03-09
- Earliest claimed: 2002-11-18
- Assignees: Santen Pharmaceutical Co., Ltd.
- Inventors: Masakazu Hatano; Tadashi Nakajima; Takeshi Matsugi; Hideaki Hara
- Web page: https://patentgrep.com/patent/US20060052367A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the β-blocker. For the administration mode, each drug can be administered in combination or in mixture.

## Claims

### Claim 1

A therapeutic agent for glaucoma comprising a combination of a Rho kinase inhibitor and a β-blocker.

### Claim 2

A therapeutic agent for glaucoma characterized in that it comprises a combination of a Rho kinase inhibitor and a β-blocker, and they complement and/or enhance their actions each other.

### Claim 3 (depends on 1, 2)

The therapeutic agent for glaucoma as claimed in claim 1 or 2, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

### Claim 4 (depends on 1, 2)

The therapeutic agent for glaucoma as claimed in claim 1 or 2, wherein the β-blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

### Claim 5

A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a β-blocker to a patient.

### Claim 6

A method of treating glaucoma characterized by administering effective amounts of a Rho kinase inhibitor in combination with a β-blocker to a patient, thereby they complementing and/or enhancing their actions each other.

### Claim 7 (depends on 5, 6)

The method of treating glaucoma as claimed in claim 5 or 6, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

### Claim 8 (depends on 5, 6)

The method of treating glaucoma as claimed in claim 5 or 6, wherein the β-blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

### Claim 9

Use of a combination of a Rho kinase inhibitor and a β-blocker in the manufacture of a therapeutic agent for glaucoma.

### Claim 10

Use of a combination of a Rho kinase inhibitor and a β-blocker in the manufacture of a therapeutic agent for glaucoma, characterized in that their actions are complemented and/or enhanced each other.

### Claim 11 (depends on 9, 10)

The use of the combination of the Rho kinase inhibitor and the β-blocker as claimed in claim 9 or 10, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane-carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

### Claim 12 (depends on 9, 10)

The use of the combination of the Rho kinase inhibitor and the β-blocker as claimed in claim 9 or 10, wherein the β-blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.
